CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies ...
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
FDA clearance of trans sodium crocetinate allows Diffusion to proceed with their latest Phase II oxygenation trial. Diffusion Pharmaceuticals, a biopharmaceutical company developing novel oxygenation ...
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy WALTHAM, Mass., Aug. 29, 2023 (GLOBE ...
CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback